Le Lézard
Classified in: Health
Subject: PDT

Introducing Proactiv's NEW Post Blemish 10% Vitamin C Serumtm Helps Even and Brighten Acne-Prone Skin


HAWTHORNE, N.Y., May 8, 2024 /PRNewswire/ -- Alchemee LLC ? Proactiv®, the trusted leader in acne skincare solutions and America's #1 Clear Skin Routine, announced the launch of its latest innovation: the Post Blemish 10% Vitamin C Serumtm. Created specifically for acne-prone skin, this unique serum is designed to visibly even and smooth the appearance of skin, helping users achieve a radiant post blemish complexion.

Crafted with a potent blend of ingredients, including 10% vitamin C (3-O-ethyl ascorbic acid), licorice root, centella asiatica, and hyaluronic acid, this post blemish serum targets post inflammatory hyperpigmentation while safeguarding against environmental stressors that can contribute to skin darkening. This fragrance free, lightweight formula is fast absorbing, creating an invisible shield that restores the skin's natural radiance and brightness.

"Our mission at Proactiv is to help people feel confident about their skin by providing effective skincare solutions," says Samantha Boulukos, Head of Business at Alchemee. "Proactiv's new serum helps fade the appearance of hyperpigmentation with skin-loving ingredients, and is a great compliment to our Proactiv skin care line."

"I've found that patients are much happier when treating acne while simultaneously addressing the dark marks it leaves behind," says Dr. Rachel Nazarian, Board Certified Dermatologist. "Improving tone with this non-comedogenic vitamin C ensures that skin brightens effectively, without causing new acne pimples. The combination of antioxidants, hydrators, and pigment-targeted ingredients work on many different pathways to enhance the skin quality."

Key ingredients include:

Features of the Post Blemish 10% Vitamin C Serumtm:

Proactiv's Post Blemish 10% Vitamin C Serumtm is now available for purchase exclusively at www.proactiv.com.  For more information about this breakthrough product and Proactiv's complete range of skincare solutions, visit www.proactiv.com.

About Alchemee LLC.

Since 1995, Proactiv has been at the forefront of acne treatment, and the brand continues to offer breakthrough solutions that meet the dynamic skincare needs of people worldwide.

Alchemee LLC, formerly The Proactiv Company, and a subsidiary of Taro Pharmaceutical Industries Ltd., is an industry leader in developing routine-based skincare solutions. Alchemee combines breakthrough medical technologies with the best acne treatment fighters into tried and true routines. With over 30 years of experience and more than 20 million customers worldwide, there's a reason Proactiv® is America's #1 Clear Skin Routine. Proactiv's trusted 3-step skincare regimens work to break the acne cycle and set users on a path to clear, confident skin.

About Taro Pharmaceutical Industries Ltd.

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com.

For media inquiries, please contact:
Lippe Taylor

[email protected]

SOURCE Proactiv


These press releases may also interest you

at 02:07
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....

at 02:05
PureTech Health plc ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces the opening of its proposed $100 million tender offer (the "Tender...

at 01:30
The global urinary catheters market  size is estimated to grow by USD 2.44 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 7.63%  during the forecast period. ...

at 00:25
Zai Lab Limited and Innoviva Specialty Therapeutics today announced that China's National Medical Products Administration (NMPA) has approved Zai Lab's New Drug Application (NDA) for XACDURO® (sulbactam-durlobactam) for the treatment of...

19 mai 2024
Frost & Sullivan recently analyzed the hospital industry and noted that operational inefficiencies, workflow interruptions and shortage of skilled healthcare professionals are some key challenges faced by the healthcare industry. Based on its...

19 mai 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...



News published on and distributed by: